A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Oct 2012 New trial record